Munzel T, Wild PS. Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service – results from the prospective, multi-center, observational cohort study thrombEVAL. During four years, ending 2014, Portavita’s solution was used in a trial in Mainz treating 760 patients with very positive results. The main conclusion that can be drawn from the thrombEVAl study and a large number of other studies regarding the necessity of the treatment is that not treating patients with anticoagulation results in a higher risk of developing complications. The cost of prevention is significantly lower than the cost of treating the complications that occur. Also the emotional and physical consequences of complications like a stroke are immense.